R75
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 66
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.370
- NOTCH_SIGNALING+0.310
- APICAL_JUNCTION+0.220
- MYOGENESIS+0.220
- INTERFERON_GAMMA_RESPONSE+0.210
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.200
- APICAL_SURFACE+0.180
- P53_PATHWAY+0.160
- WNT_BETA_CATENIN_SIGNALING+0.120
- HEDGEHOG_SIGNALING+0.100
Top 10 suppressed
- MYC_TARGETS_V1-0.460
- E2F_TARGETS-0.420
- PROTEIN_SECRETION-0.420
- G2M_CHECKPOINT-0.400
- MTORC1_SIGNALING-0.350
- SPERMATOGENESIS-0.340
- PANCREAS_BETA_CELLS-0.290
- UNFOLDED_PROTEIN_RESPONSE-0.270
- ANDROGEN_RESPONSE-0.260
- TNFA_SIGNALING_VIA_NFKB-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8942967 | — | — | 0.805 |
| 2 | SRR1516086 | — | — | 0.795 |
| 3 | MDT-AP-0820 | Med | Medulloblastoma | 0.745 |
| 4 | R109 | — | — | 0.720 |
| 5 | R147 | — | — | 0.717 |
| 6 | 18f03a3f-c2d2-4c3b-a246-e8a78e6aa479 | — | — | 0.716 |
| 7 | 002260fb-3015-4876-b8fd-edffd7fc95e8 | — | — | 0.713 |
| 8 | MNG1238 | — | — | 0.710 |
| 9 | TCGA-A7-A3J1-01A-11R-A213-07 | — | A | 0.700 |
| 10 | MDT-AP-0759 | Med | Medulloblastoma | 0.697 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.370 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.310 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.220 | Inavolisib | — uncovered |
| MYOGENESIS | 0.220 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.210 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.200 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.180 | Temsirolimus | — uncovered |
| P53_PATHWAY | 0.160 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.120 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.100 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.090 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.070 | Inavolisib | — uncovered |
| APOPTOSIS | 0.060 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.060 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.060 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.050 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.050 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.040 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.040 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.020 | Inavolisib | — uncovered |